When 'To Do No Harm' May Not Be an Option
(Philadelphia,
PA) - In light of the recent event at a Moscow theater
where an experimental gas was used to disable terrorists
- and the overwhelming concern about weapons of mass
destruction - the need for greater experimentation on
humans seems clear. To find biomedical countermeasures
to chemical and biological weapons, human test subjects
will, by necessity, be deliberately exposed to harmful
agents. In an editorial in the November 1st issue of
the journal Science, Arthur L. Caplan, PhD
and Pamela Sankar, PhD, bioethicists at the University
of Pennsylvania School of Medicine, examine the
pressing need to establish guidelines for exposing human
test subjects to higher-than-normal levels of risk in
order to determine the efficacy of potential cures.
"If they haven't begun already, it is inevitable
that human subjects will be needed to test the safety
of antidotal measures to chemical or biological weapons,"
says Caplan, the Emanuel and Robert Hart Professor of
Bioethics and Chair of Penn's Department of Medical
Ethics. "While the specifics and the results of
such tests may necessarily be secret, it is important
that we discuss how trials would be conducted and how
we will use those findings as best as possible."
In developing effective vaccines or counter-agents,
medical science should not sacrifice safety for speed,
according to Caplan and Sankar. The bioethicists remind
academic institutional review boards - the panels that
oversee the formulation of experimental protocols -
of their duty to establish guidelines for fair and humane
treatments of human test subjects.
In their editorial, Caplan and Sankar state that "these
guidelines must also address who may be recruited as
subjects, what level of competency they should demonstrate,
how the freedom of their choice can be ensured, what
types of end points will be used, what compensation
they will be given, and what level of oversight will
be in place."
# # #
.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.